Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 2/20 | 0.33 |
| ▸ | HEXA | P06865 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090621 | 1.00 | LGALS8 (0.39) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL15682355 | 1.00 | LGALS8 (0.39) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL18720660 | 1.00 | LGALS8 (0.39) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL12170361 | 1.00 | LGALS8 (0.39) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL13264503 | 1.00 | LGALS8 (0.39) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL17518978 | 0.84 | FUCA1 (0.37) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL18512700 | 0.82 | ALDH1A1 (0.35) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL16299502 | 0.82 | ALDH1A1 (0.35) | LGALS8LGALS1LGALS3LGALS9L3MBTL1 | |
| SCHEMBL14090616 | 0.82 | OGA (0.31) | OGA | |
| SCHEMBL14501718 | 0.82 | OGA (0.31) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771578-B2 | Phosphorous-linked oligomeric compounds and their use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170268002-A1 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | Regulus Therapeutics Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9752146-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9708610-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9663787-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170037402-A1 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | Regulus Therapeutics Inc. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037403-A1 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | Regulus Therapeutics Inc. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9528108-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAS | Regulus Therapeutics Inc. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9476051-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9447412-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAS | Regulus Therapeutics Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-7339051-B2 | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) | ISIS PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080051359-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION | KARRAS JAMES G | 2008-02-28 | — | — | US | disclosed |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ALLERSON CHARLES | 2008-02-14 | — | — | US | disclosed |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-7307069-B2 | Antisense oligonucleotide modulation of STAT3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7235653-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070135364-A1 | Compositions and methods for the modulation of the expression of b7 protein | ISIS PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | BIOGEN MA INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | BANK OF AMERICA, N.A. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051359-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION | STAT3, STAT1, STAT6 | LGALS8 1674/4885LGALS1 2348/4885LGALS3 2546/4885 |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | CD2BP2, MICA, CD74 | LGALS8 505/4885LGALS1 488/4885LGALS3 688/4885 |
| US-20070135364-A1 | Compositions and methods for the modulation of the expression of b7 protein | CD2BP2, CD74, CD47 | LGALS8 633/4885LGALS1 679/4885LGALS3 619/4885 |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | SOD1, SOD3, RNASE1 | LGALS8 1498/4885LGALS1 1083/4885LGALS3 2653/4885 |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | LGALS8 488/4885LGALS1 1159/4885LGALS3 1304/4885 |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | RPP30, NOP10, NR0B1 | LGALS8 4854/4885LGALS1 4874/4885LGALS3 4853/4885 |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | NSUN2, NSUN3, RNMT | LGALS8 2103/4885LGALS1 3385/4885LGALS3 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.